Please assess the completion status of the following clinical trial:

Trial Title: Aspirin for Venous Ulcers: Randomised Trial (AVURT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Those with at least one chronic venous leg ulcer - where chronic venous leg ulceration is defined as any break in the skin which has either: a) been present for more than six weeks, or b) occurred in a person with a history of venous leg ulceration. Ulcers will be considered purely venous if clinically no other etiology was suspected. For this the ulcer must be venous in appearance (i.e. moist, shallow, of an irregular shape) and lie wholly or partially within the gaiter region of the leg. If the patient has more than one ulcer we will choose the largest ulcer as the 'index' lesion for purposes of the analysis.~* Ulcer area \> 1 square cm~* Participants must have had an ankle brachial pressure index (ABPI) ≥ 0.8 taken within the previous three months. When the ABPI is incompressible other forms of assessment including peripheral pulse examination / toe pressure / duplex ultrasound in combination with clinical judgement to be used to exclude PAD~* Aged ≥ 18 years (no upper age limit)~* Able and willing to provide informed consent~* Ulcer duration \> 6 weeks or prior history of venous ulceration.~Exclusion Criteria:~* Unable to provide consent~* Unwilling to provide consent~* Foot (below the ankle) ulcer~* A leg ulcer of non-venous aetiology (i.e. arterial)~* Ankle-brachial pressure index (ABPI) \<0.8~* Current regular use of aspirin (as may be randomised to placebo)~* Previous intolerance of aspirin / contraindication to aspirin (decision made according to the prescribers' clinical judgement)~* Prohibited medication: Probenecid~* Known lactose intolerance (as placebo contains lactose)~* Pregnant/lactating women~* Currently participating in another study evaluating leg ulcer therapies.~* Another reason that excluded them from participating within this trial (decision made according to the nurses' or prescribers' clinical judgment )\*~* Previously been recruited in to this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin (Type: EXPERIMENTAL): Aspirin 300mg capsule by mouth once a day for 24 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsule (for aspirin 300mg capsule) by mouth once a day for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).